All In Biotech

Drug Trial Radar · NCT02466490

Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension

A 24-week Trial of the Effectiveness and Safety of Fimasartan 60 mg Alone as Initial Treatment and Its Randomized Escalation to Fimasartan 120 mg or Fimasartan 60 mg/HCTZ 12.5 mg in Mexican Patients With Grade 1 and 2 Essential Hypertension

Last checked: Nov 19, 2026Latest source record: Jun 9, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 272 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

272

Actual

Start

Apr 2013

Primary completion

Feb 2014

Study completion Feb 2014

Sponsor

Lead sponsor
Stendhal Americas, S.A.Industry
Sponsor type
Industry
First posted
Jun 9, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Fimasartan (FMS) is an AT1 receptor antagonist indicated for once a day administration, currently approved for the treatment of essential hypertension in Corea and Mexico. As the safety and efficacy of FMS was initially demonstrated in Korea only, it was necessary to address the potential for ethnic factors to have an effect on the drug´s efficacy and safety in the Mexican population. To address this need, a cohort of 272 Mexican subjects with grades 1-2 essential hypertension were sequentially treated on a treat to target basis (target: sitting Diastolic Blood Pressure (sDBP) \<90 mmHg) with 60 mg FMS once a day (8 weeks), either 120 mg FMS or 60 mg FMS+12.5 mg HCTZ once a day (randomized 4 week treatment period) and 120 mg FMS once a day (during 12 weeks) for a total treatment period of 24 weeks.

Conditions

  • Hypertension, Essential

Interventions

  • FimasartanDrug

    Fimasartan tablets

  • Fimasartan; HydrochlorothiazideDrug

    Fimasartan plus hydrochlorothiazide fixed dose combination tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Blood Pressure Change From BaselineTime frame: Baseline to Treatment Week 8

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital de Jesús IAP

    México, D.f., Mexico

  • Hospital General de Ticomán

    México, D.f., Mexico

  • Centro Médico Exel

    Tijuana, Estado de Baja California, Mexico

  • Hospital Civil de Guadalajara Fray Antonio Alcalde

    Guadalajara, Jalisco, Mexico

  • Unidad de Investigación Clínica Cardiometabólica de Occidente

    Guadalajara, Jalisco, Mexico

  • Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara

    Guadalajara, Jalisco, Mexico

  • Icle S.C.

    Guadalajara, Jalisco, Mexico

  • Núcleo Médico La Paz

    Guadalajara, Jalisco, Mexico

  • Hospital Dr. Ángel Leaño

    Zapopan, Jalisco, Mexico

  • Instituto Jalisciense de Investigación en Diabetes y Obesidad S. C.

    Guadalajara, Jalsico, Mexico

  • Cardiolink Clintrials

    Monterrey, Nuevo León, Mexico

  • Centro de Estudios Clínicos y Especialidades Médicas

    Monterrey, Nuevo León, Mexico

  • Hospital Dr. Ignacio Morones Prieto

    San Luis Potosí City, San Luis Potosí, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.